Anzeige
❌
Mehr »
Sonntag, 22.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AB

WKN: A41Z2Z | ISIN: SE0029278555 | Ticker: BTP
Frankfurt
20.11.26 | 08:04
0,264 Euro
+0,76 % +0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTIVE BIOTECH AB Chart 1 Jahr
5-Tage-Chart
ACTIVE BIOTECH AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,2780,32719:02

Aktuelle News zur ACTIVE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.11.Active Biotech AB: Active Biotech Interim Report Q3 2026171EVENTS DURING THE THIRD QUARTERFirst patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis (July 24)Active Biotech expanded US collaboration to advance tasquinimod clinical...
► Artikel lesen
ACTIVE BIOTECH Aktie jetzt für 0€ handeln
13.10.Active Biotech AB: First cohort under amended protocol succesfully completes safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis313Lund, Sweden - October 13, 2026 Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first safety cohort of three patients enrolled under the amended protocol has successfully completed...
► Artikel lesen
30.09.Active Biotech AB: Active Biotech Strengthens Global Patent Protection for Laquinimod with Patent Grant in Japan426Lund, September 30, 2026, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the Japan Patent Office has formally granted the company's patent application covering an ophthalmic formulation...
► Artikel lesen
20.08.Active Biotech AB: Active Biotech Interim Report Q2 2026411EVENTS DURING THE SECOND QUARTERPreclinical data with tasquinimod in myelodysplastic neoplasms published in HemaSphere (April 14)Active Biotech publishes results from the LION study on ocular absorption...
► Artikel lesen
18.08.Active Biotech AB: Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis418Lund, Sweden, August 18, 2026 - Active Biotech (NASDAQ Stockholm: ACTI) today announced it has entered a collaboration agreement with the Icahn School of Medicine at Mount Sinai, New York, US, a not-for-profit...
► Artikel lesen
24.07.Active Biotech AB: First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis404Lund Sweden, July 24, 2026 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the Phase Ib/II clinical study of tasquinimod following an amendment to...
► Artikel lesen
03.06.XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2026943The following instruments on XETRA do have their first trading 03.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2026 Aktien 1 US3143521058 FedEx Freight Holding...
► Artikel lesen
02.06.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2026851The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2026.ISIN NameFR001400BMH7 TeractLU0094159042 BNP...
► Artikel lesen
02.06.XFRA ISIN CHANGE592Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA29391A1030 Epic Gold Corp. 02.06.2026 CA29391A2020 Epic Gold Corp. 03.06.2026 Tausch 5:1SE0001137985 Active Biotech...
► Artikel lesen
02.06.XFRA CAPITAL ADJUSTMENT INFORMATION - 02.06.20261.029 Das Instrument VIS ES0184262212 VISCOFAN SA INH. EO 0,70 EQUITY wird cum Kapitalmassnahme gehandelt am 02.06.2026 und ex Kapitalmassnahme am 03.06.2026 The instrument VIS ES0184262212 VISCOFAN SA INH....
► Artikel lesen
29.05.Split and Change of ISIN for Active Biotech AB572The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from Jun 3, 2026. The order book will not change. Short...
► Artikel lesen
28.05.Active Biotech AB: Active Biotech announces timetable for reverse share split879The Annual General Meeting in Active Biotech AB (publ) ("Active Biotech" or the "Company") held on May 20, 2026, resolved to carry out a reverse share split 1:100, whereby hundred (100) shares are consolidated...
► Artikel lesen
20.05.Active Biotech AB: Annual General Meeting of Active Biotech AB262The Annual General Meeting of Active Biotech was held on May 20, 2026. The following main resolutions were passed.In accordance with the Board of Directors' proposal, it was resolved that no dividend...
► Artikel lesen
13.05.Active Biotech AB: European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON404Lund, Sweden - May 13, 2026 Active Biotech (NASDAQ Stockholm: ACTI) today announced positive feedback from the European regulatory authorities and ethics committee regarding the clinical proof-of-concept...
► Artikel lesen
07.05.Active Biotech AB: Active Biotech Interim Report Q1 2026422EVENTS DURING THE FIRST QUARTERThe US Patent Office (US PTO) granted a patent related to a pharmaceutical formulation of tasquinimod (January)Active Biotech receives positive feedback on its clinical...
► Artikel lesen
12.02.Active Biotech AB: Active Biotech Year End Report 2025808FOURTH QUARTER IN BRIEFActive Biotech announced a fully secured rights issue, subject to approval by an extraordinary general meeting, of approximately SEK 70 million before transaction costs (October...
► Artikel lesen
10.02.Active Biotech AB: Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis640Lund, Sweden - February 10, 2026 -Active Biotech (NASDAQ Stockholm: ACTI) today received positive feedback on its clinical proof-of-concept trial with tasquinimod in myelofibrosis. The study will now...
► Artikel lesen
10.12.25Active Biotech AB: Active Biotech announces outcome in the rights issue549NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND...
► Artikel lesen
25.11.25Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US741Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application related...
► Artikel lesen
24.11.25Listing of subscription rights and paid subscription shares of Active Biotech AB546With effect from November 25, 2025, the subscription rights of Active Biotech AB will be traded on the list for Equity rights. Trading will continue up until and including December 04, 2025. Instrument: Subscription...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2